Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial

Abstract: Background
Bimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis.

Objective
Evaluate the safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis.

Methods
The BE RADIANT phase 3b randomized controlled trial consisted of a 48-week double-blinded period, where patients received bimekizumab (320 mg every 4 or 8 weeks) or secukinumab (300 mg weekly to Week 4, then every 4 weeks), and an open-label extension (OLE). From Week 48, all patients received bimekizumab in the OLE.

Results
At Week 48, more patients achieved complete skin clearance (PASI 100; modified non-responder imputation) with bimekizumab than secukinumab (74.8% vs 52.8%). PASI 100 responses were maintained to Week 96 in continuous bimekizumab patients (70.8%); patients who switched from secukinumab to bimekizumab had increased rates at Week 96 (76.6%). The most common adverse events were: nasopharyngitis, oral candidiasis, and urinary tract infection. Safety data were consistent with the known safety profile of bimekizumab.

Limitations
Limited racial diversity; overlap with the COVID-19 pandemic.

Conclusions
High PASI 100 responses achieved with bimekizumab over 48 weeks were sustained through Week 96; secukinumab patients who switched to bimekizumab achieved similar responses by Week 96

Angaben zum Objekt

• Standort: Deutsche Nationalbibliothek Frankfurt am Main
• Umfang: Online-Ressource
• Sprache: Englisch
• Anmerkungen: Journal of the American Academy of Dermatology. - 89, 3 (2023) , 486-495, ISSN: 1097-6787

Beteiligte, Orts- und Zeitangaben

• Ereignis: Veröffentlichung
• (wo): Freiburg
• (wer): Universität
• (wann): 2023
• Urheber: Strober, Bruce ; Paul, Carle F. ; Blauvelt, Andrew ; Thaci, Diamant ; Puig, Luis ; Lebwohl, Mark G. ; White, Katy ; Vanvoorden, Veerle ; Deherder, Delphine ; Gomez, Natalie Nunez ; Eyerich, Kilian

Weitere Informationen

• DOI: 10.1016/j.jaad.2023.04.063
• URN: urn:nbn:de:bsz:25-freidok-2371750
• Rechteinformation: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Letzte Aktualisierung: 14.08.2025, 10:45 MESZ